Stocks TradingCharts.com

stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Search
Symbol Search Browse Symbols My Charts Menu
QUICK QUOTE
QUICK CHART
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts

Trulieve Reports Third Quarter 2026 Results

November 5, 2026 (CNW Group via COMTEX) --
  • Third quarter revenue of $230 million, with 64% gross margin
  • Cash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026
  • Received final DEA registrations pursuant to final order rescheduling state licensed medical marijuana to Schedule III under the Controlled Substances Act

TALLAHASSEE, Fla., Nov. 5, 2026 /CNW/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced its results for the quarter ended September 30, 2026. Results are reported in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unless otherwise indicated. Numbers may not sum perfectly due to rounding.

Trulieve logo

Q3 2026 Financial and Operational Highlights*

  • Revenue of $230 million, with 95% of revenue from retail sales.
  • Achieved gross margin of 64%, with gross profit of $148 million.
  • Reported positive net income attributable to common shareholders of $1 million. Adjusted net income of $18 million* excludes non-recurring charges, asset impairments, disposals, and unconsolidated entity.
  • Achieved adjusted EBITDA of $89 million*, or 39% of revenue.
  • Generated cash flow from operations of $74 million and free cash flow of $45 million*.
  • Cash at quarter end was $327 million.
  • Realized seven-fold increase in traffic in Georgia following medical cannabis program expansion on July 1 with new product launches including Modern Flower and Roll One.
  • Completed corporate domestication to Delaware from British Columbia.
  • Rang The Closing Bell at the New York Stock Exchange to commemorate NYSE listing.
  • Added to the S&P Total Market Index (TMI), S&P Completion Index (CI) and Morningstar Total Stock Market Index.
  • Closed perpetual royalty free license for Alien Labs and Connected branded cannabis products in Florida and Texas that includes genetics, trademarks, and proprietary know-how and a right of first refusal for exclusive licensing rights in additional expansion markets.
  • Opened two dispensaries in Marco Island, Florida, and Dunwoody, Georgia.

*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for Non-GAAP metrics.

Recent Developments

  • Received final registrations from the Drug Enforcement Agency for state licensed medical marijuana dispensaries as part of federal regulatory framework for qualified medical marijuana businesses under the Controlled Substances Act.
  • Repaid $65 million mortgage notes payable ahead of maturity in 2028 secured by cultivation site in Jefferson County, Florida to reduce leverage and interest expense.
  • Currently operate 208 retail dispensaries and 3.5 million square feet of cultivation and processing capacity in the United States.

Management Commentary

"State licensed medical marijuana rescheduling unlocked major milestones including DEA registration, removal of 280E tax, and uplisting to the NYSE," said Kim Rivers, Trulieve CEO. "Third quarter results demonstrate the strength of our medical cannabis platform underscored by revenue, margins, and cash generation. With meaningful growth expansion opportunities in Georgia and Texas, we are in the early stages of an accelerated growth cycle."

Financial Highlights*

Third quarter 2026 results include only Trulieve medical operations. Prior periods include consolidated results including Harvest mixed medical and adult use operations.

Results of Operations

For the Three Months Ended

For the Nine Months Ended

(Figures in millions except
per share data)

September
30, 2026

September
30, 2025

%
Better /
(Worse)

June 30,
2026
†

%
Better /
(Worse)

September
30, 2026

September
30, 2025

%
Better /
(Worse)

Revenue

$

230

$

288

(20 %)

$

271

(15 %)

$

788

$

888

(11 %)

Gross profit

$

148

$

170

(13 %)

$

162

(9 %)

$

480

$

536

(10 %)

Gross margin %


64 %


59 %



60 %



61 %


60 %


Operating expenses

$

106

$

128

17 %

$

533

80 %

$

773

$

408

(89 %)

Operating expenses %


46 %


44 %



197 %



98 %


46 %


Net income (loss)**

$

1

$

(27)

NMF

$

(406)

NMF

$

(403)

$

(73)

NMF

Net income (loss) continuing operations

$

1

$

(24)

NMF

$

(405)

NMF

$

(401)

$

(72)

NMF

Adjusted net income (loss)

$

18

$

(12)

NMF

$

20

(12 %)

$

59

$

(24)

NMF

Diluted shares outstanding


201


191



193



193


191


Diluted EPS continuing operations

$

0.00

$

(0.11)

NMF

$

(2.10)

NMF

$

(2.08)

$

(0.35)

NMF

Adjusted Diluted EPS

$

0.09

$

(0.07)

NMF

$

0.11

(15 %)

$

0.30

$

(0.12)

NMF

Adjusted EBITDA

$

89

$

103

(13 %)

$

98

(9 %)

$

288

$

322

(11 %)

Adjusted EBITDA Margin %


39 %


36 %



36 %



36 %


36 %



NMF - No Meaningful Figure

†Q2:26 reported results reflect the deconsolidation of Harvest mixed medical and adult use operations on June 3, 2026.   

*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for Non-GAAP metrics.

**Net income (loss) attributable to common shareholders which excludes non-controlling interest.

Conference Call 
The Company will host a conference call and live audio webcast on November 5, 2026, at 8:30 A.M. Eastern time, to discuss its third quarter 2026 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.

North American toll free: 1-844-824-3830


Passcode: 8639220




International: 1-412-542-4136


Passcode: 8639220

A live audio webcast of the conference call will be available at:
Trulieve Third Quarter 2026 Results Call

A powerpoint presentation and archived replay of the webcast will be available at:
https://investors.trulieve.com/events 

The Company's Form 10-Q for the quarter ended September 30, 2026 will be available on the SEC's website or at https://investors.trulieve.com/quarterly-results. The Company's Management's Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company's profile on https://www.sedarplus.ca and on its website at https://investors.trulieve.com/quarterly-results. This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.

Trulieve Cannabis Corp.

Condensed Consolidated Balance Sheets (Unaudited)

(in millions, except for share data) 



September 30,
2026


December 31,
2025

ASSETS




Current Assets:




Cash and cash equivalents

$          326.7


$          255.5

Accounts receivable, net

3.8


10.5

Inventories

190.8


242.3

Income tax receivable

0.5


8.5

Prepaid expenses

17.5


18.3

Other current assets

2.3


26.7

Management services agreement receivable, related party

21.3


—

Assets associated with discontinued operations

—


0.9

Total current assets

562.8


562.7

Property and equipment, net

592.9


670.4

Right of use assets - operating, net

90.0


108.3

Right of use assets - finance, net

55.7


60.0

Intangible assets, net

335.0


798.4

Goodwill

325.6


483.9

Investment in Harvest

146.1


—

Other assets

10.0


10.5

Long-term assets associated with discontinued operations

—


1.9

TOTAL ASSETS

$        2,118.2


$        2,696.1

LIABILITIES




Current Liabilities:




Accounts payable and accrued liabilities

$             68.2


$             82.7

Deferred revenue

5.9


9.6

Notes payable - current portion

4.2


4.1

Operating lease liabilities - current portion

11.9


13.0

Finance lease liabilities - current portion

10.7


10.7

Construction finance liabilities - current portion

0.7


2.4

Contingencies

0.3


0.8

Liabilities associated with discontinued operations

—


3.7

Total current liabilities

102.0


126.9

Long-Term Liabilities:




Notes payable, net

88.7


90.8

Private placement notes, net

196.0


136.7

Operating lease liabilities

89.3


107.9

Finance lease liabilities

60.5


64.1

Construction finance liabilities

120.2


133.8

Deferred tax liabilities

55.4


178.0

Uncertain tax position liabilities

625.4


668.4

Other long-term liabilities

9.3


11.4

Long-term liabilities associated with discontinued operations

—


34.9

TOTAL LIABILITIES

$        1,346.7


$        1,553.1

EQUITY




Common shares, no par value; unlimited shares authorized; None issued and
outstanding as of September 30, 2026 and 169,313,023 shares issued and
outstanding as of December 31, 2025

$                —


$                —

Preferred stock, $0.0001 par value; 1,000,000,000 shares authorized; none
issued and outstanding as of September 30, 2026 and December 31, 2025

—


—

Class A subordinate voting common stock, $0.0001 par value per share;
5,000,000,000 shares authorized; 170,347,610 shares issued and outstanding as
of September 30, 2026 and none issued and outstanding as of December 31,
2025

0.0


—

Class B multiple voting common stock, $0.0001 par value per share; 300,000
shares authorized; 224,064 shares issued and outstanding as of September 30,
2026 and none issued and outstanding as of December 31, 2025

—


—

Additional paid-in-capital

2,088.0


2,073.4

Accumulated deficit

(1,314.8)


(912.1)

Non-controlling interest

(1.7)


(18.2)

TOTAL EQUITY

771.5


1,143.0

TOTAL LIABILITIES AND EQUITY

$        2,118.2


$        2,696.1

 

Trulieve Cannabis Corp.

Condensed Consolidated Statements of Operations (Unaudited)

(in millions, except for per share data)



Three Months Ended
September 30,


Nine Months Ended
September 30,


2026


2025


2026


2025

Revenue

$    230.2


$    288.2


$    787.9


$    888.0

Cost of goods sold

82.2


118.3


307.5


352.0

Gross profit

148.0


169.9


480.4


536.0

Expenses:








Selling, general, and administrative

87.8

Do not sell my personal information

Copyright © 2026. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.